Journal
THERANOSTICS
Volume 9, Issue 26, Pages 8018-8025Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.38587
Keywords
Transcytosis; EPR effect; nano drug delivery
Categories
Funding
- U.S. Public Health Service Grant [1U01CA198846]
- NATIONAL CANCER INSTITUTE [U01CA198846] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Numerous nano drug delivery systems have been developed for preclinical cancer research in the past 15 years with the hope for a fundamental change in oncology. The robust nanotherapeutic research has yielded early-stage clinical products as exemplified by the FDA-approved nano formulations (Abraxane (R) for paclitaxel and Onyvide (R) for irinotecan) for the treatment of solid tumors, including pancreatic ductal adenocarcinoma (PDAC). It is generally believed that enhanced permeability and retention (EPR) plays a key role in nanocarriers' accumulation in preclinical tumor models and is a clinically relevant phenomenon in certain cancer types. However, use of EPR effect as an across-the-board explanation for nanoparticle tumor access is likely over-simplified, particularly in the stroma rich solid tumors such as PDAC. Recently, ample evidences including our own data showed that it is possible to use transcytosis as a major mechanism for PDAC drug delivery. In this mini-review, we summarize the key studies that discuss how transcytosis can be employed to enhance EPR effect in PDAC, and potentially, other cancer malignancies. We also mentioned other vasculature engineering approaches that work beyond the classic EPR effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available